clinical trial · NCT05279131
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
Almirall, S.A.·phase3·completed·n = 105
Keratosis, ActinicTirbanibulin ointment 1%
brief summary
The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm\^2 on the face or balding scalp.
started
Jun 28, 2022
primary completion
Dec 28, 2022
completion
Dec 28, 2022
last updated
Jan 23, 2024
official title
A Phase 3, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% Applied to a Field of Approximately 100 cm2 on the Face or Balding Scalp in Adult Patients With Actinic Keratosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol